Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Axitinib + MEDI5752 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Axitinib | Inlyta | AG-013736|AG013736 | KIT Inhibitor 57 PDGFR Inhibitor (Pan) 30 VEGFR Inhibitor (Pan) 36 | Inlyta (axitinib) inhibits the VEGFRs, PDGFR, and KIT, potentially resulting in decreased angiogenesis and reduced tumor growth (PMID: 16027439, PMID: 25709499). Inlyta (axitinib) is approved for renal cell carcinoma (FDA.gov). |
MEDI5752 | MEDI-5752|MEDI 5752|volrustomig | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 148 PD-L1/PD-1 antibody 119 | MEDI5752 is a bispecific human IgG1 monoclonal antibody that binds PD1 (PDCD1) and CTLA4, potentially resulting in enhanced anti-tumor immune response (Cancer Res 2018;78(13 Suppl):Abstract nr 2776). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04522323 | Phase I | Axitinib + MEDI5752 | A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma | Recruiting | USA | FRA | ESP | AUS | 0 |